Trenchant Technologies Capital Corp. (CSE:AITT)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.79M -36.7% |
| Revenue (ttm) | n/a |
| Net Income | -4.85M |
| EPS | -0.07 |
| Shares Out | 75.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,580 |
| Average Volume | 50,342 |
| Open | 0.0500 |
| Previous Close | n/a |
| Day's Range | 0.0500 - 0.0500 |
| 52-Week Range | 0.0100 - 0.2000 |
| Beta | -1.37 |
| RSI | 45.36 |
| Earnings Date | n/a |
About CSE:AITT
Trenchant Technologies Capital Corp. is a private equity and venture capital firm specializing in early-stage, turnaround, special situation debt financing in private equity companies. The firm prefers to invest in novel technologies including Artificial Intelligence, Quantum Computing, and traditional businesses primarily in the medical, biomedical, and technology sectors. It seeks to invest in Canada. It invests in companies that are financially sound, with minimal debt and a clear pathway to significant revenue generation. The company was fo... [Read more]
Financial Performance
Financial StatementsNews
Trenchant Technologies Capital Corp. Announces Unwinding of Previous Limitless Quantum Acquisition
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has entered into a shar...
Trenchant Announces Closing of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC: AITTF) ("Trenchant" or the "Company") announces that, further to its News Release...
GNQ Insilico's AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated Clinical Drug Trial
GNQ Insilico's ("GNQ") proprietary genomics-driven platform is leveraging Artificial Intelligence (AI) and Quantum Computing technologies to create "intelligent digital twins " of human patients that ...